8-K: Xeris Biopharma Exceeds 2025 Revenue Guidance

Xeris Biopharma Holdings, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, expecting record total revenue of $292 million, surpassing its guidance.

Summary

• Anticipates full-year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million.
• This represents a 44% growth compared to the prior year.
• Fourth quarter 2025 Recorlev net revenue is expected to be $45 million, with full-year 2025 Recorlev net revenue at $139 million.
• Recorlev ended the year with approximately 700 patients on therapy, and commercial expansion was executed as planned.
• Gvoke revenue grew more than 13% compared to the prior year.
• Keveyis finished the year with a growing patient base and a greater number of patients on therapy compared to year-end 2024.
• Delivered positive Adjusted EBITDA in every quarter of 2025.
• Strengthened intellectual property portfolio with a new Orange Book-listed U.S. patent for Recorlev and a composition of matter patent for XP-8121.
• Presented long-term financial targets and a strategic vision at the company's first Analyst and Investor Day.

Sentiment

Score: 8

Explanation: The filing reports preliminary financial results that exceed prior guidance, indicating strong performance across key products and positive momentum. Management expresses excitement for future growth and highlights a robust balance sheet and strengthened IP. The only cautionary elements are standard forward-looking risk disclosures.

Positives

• Full-year 2025 total revenue of $292 million exceeded the high end of the guidance range ($285-$290 million).
• Achieved 44% total revenue growth compared to the prior year.
• Recorlev net revenue of $139 million for the full year and $45 million for Q4 2025 indicates strong product performance.
• Recorlev reached approximately 700 patients on therapy, with successful commercial expansion.
• Gvoke revenue grew over 13% year-over-year.
• Keveyis saw a growing patient base, increasing patients on therapy compared to year-end 2024.
• Maintained positive Adjusted EBITDA in every quarter of 2025.
• Enhanced intellectual property portfolio with new patents for Recorlev and XP-8121, reinforcing long-term protection.
• Demonstrated a clear strategic vision and long-term financial targets at its first Analyst and Investor Day.

Risks

• Financial position and need for financing to fund product development programs or commercialization efforts.
• Ability of products to achieve and maintain market acceptance in a competitive business environment.
• Reliance on third-party suppliers, including single-source suppliers.
• Reliance on third parties to conduct clinical trials.
• Ability of product candidates to compete successfully with existing and new drugs.
• Ability to protect intellectual property and proprietary technology.
• Accuracy and completeness of assumptions and ability to accurately estimate future financial results and market opportunities.
• General macroeconomic and geopolitical conditions, including the possibility of an economic downturn.
• Changes in governmental priorities and resources, announced or implemented tariffs or export controls, and market volatility.

Future Outlook

The company is incredibly excited about the opportunities ahead, entering 2026 with strong commercial momentum, a robust balance sheet, and a clear, disciplined strategy to fuel sustained, long-term, rapid growth across the business. They plan to announce full-year 2025 financial results and the 2026 outlook on March 2, 2026. The pipeline includes XP-8121, a Phase 3-ready asset, and multiple early-stage programs leveraging XeriSol and XeriJect technology platforms.

Management Comments

• "Our fourth quarter performance capped off a truly transformative 2025. Recorlev delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year."
• "When combined with the stellar contributions of Gvoke and Keveyis, we expect total revenue of approximately $292 million, exceeding the high end of our full-year 2025 guidance."
• "As we look ahead, we are incredibly excited about the opportunities before us. We enter the year with strong commercial momentum, supported by a robust balance sheet and a clear, disciplined strategy to fuel sustained, long-term, rapid growth across the business."

Industry Context

Xeris Biopharma operates in the specialized biopharmaceutical sector, focusing on rare diseases and conditions like Cushing's syndrome, severe hypoglycemia, and primary periodic paralysis. The strong revenue growth and exceeding guidance suggest effective commercialization strategies and market penetration for its niche products, potentially outperforming general market trends for similar-sized biopharma companies. The strengthening of its IP portfolio is crucial in this innovation-driven industry to protect future revenue streams.

Stakeholder Impact

• Shareholders: Positive impact due to exceeding revenue guidance, strong product performance, and positive Adjusted EBITDA, potentially leading to increased investor confidence and share price appreciation.
• Employees: Positive impact from strong company performance and growth, potentially leading to job security and opportunities.
• Customers/Patients: Continued access to therapies like Recorlev, Gvoke, and Keveyis, with potential for new treatments from the pipeline.
• Suppliers/Creditors: Positive outlook on the company's financial health, indicating reliability.

Next Steps

• Announce full-year 2025 financial results and 2026 outlook on March 2, 2026.
• Continue advancing the XP-8121 pipeline program towards Phase 3.
• Further develop early-stage programs leveraging XeriSol and XeriJect technology platforms.
• Execute a disciplined strategy to fuel sustained, long-term, rapid growth across the business.

Key Dates

Recommendation

The company has demonstrated strong operational execution, exceeding its own revenue guidance for the full year 2025 with significant year-over-year growth. Key products like Recorlev, Gvoke, and Keveyis are performing well, with Recorlev outperforming expectations and expanding its patient base. The achievement of positive Adjusted EBITDA in every quarter indicates financial discipline and operational efficiency. Furthermore, the strengthening of the intellectual property portfolio provides long-term asset protection, and the pipeline, including a Phase 3-ready asset, suggests future growth potential. Management's confident outlook for sustained, rapid growth, supported by a robust balance sheet, reinforces a positive investment thesis. These factors collectively point to a company with strong momentum and favorable prospects.

Keywords

Xeris Biopharma, XERS, Biopharma, Pharmaceuticals, Revenue, Financial Results, Recorlev, Gvoke, Keveyis, Cushing's Syndrome, Hypoglycemia, Primary Periodic Paralysis, XP-8121, Intellectual Property, EBITDA, SEC Filing, 8-K